Design, preparation, in vitro and in vivo evaluation of 99mTc-N2S2-Tat(49-57)-bombesin: A target-specific hybrid radiopharmaceutical

International Journal of Pharmaceutics

Volumn 375, Issue 1-2, 2009, Pages 75-83

  Santos Cuevas, Clara L ^a,b   Ferro Flores, Guillermina ^a   Arteaga de Murphy, Consuelo ^c   Ramírez, Flor de M ^a   Luna Gutiérrez, Myrna A ^a,b   Pedraza López, Martha ^c   García Becerra, Rocío ^c   Ordaz Rosado, David ^c  

^a INSTITUTO NACIONAL DE INVESTIGACIONES NUCLEARES   (Mexico)

^b UNIVERSIDAD AUTÓNOMA DEL ESTADO DE MÉXICO   (Mexico)

^c INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

Author keywords

Hybrid radiopharmaceutical; Peptide receptor imaging; Radiolabeled bombesin; Tat bombesin

Indexed keywords

BOMBESIN DERIVATIVE; CELL RECEPTOR; CYSTEINE; RADIOPHARMACEUTICAL AGENT; TECHNETIUM 99M;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BREAST CARCINOMA; CANCER CELL CULTURE; CELL STRAIN MCF 7; CONTROLLED STUDY; DRUG DESIGN; DRUG DISTRIBUTION; DRUG PURITY; DRUG RECEPTOR BINDING; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG UPTAKE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IMAGING SYSTEM; IN VITRO STUDY; IN VIVO STUDY; INTERNALIZATION; MALE; MOLECULAR MODEL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; RADIOACTIVITY; SERUM;

ANIMALS; BOMBESIN; BREAST NEOPLASMS; CELL LINE, TUMOR; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG DELIVERY SYSTEMS; DRUG STABILITY; FEMALE; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; ORGANOTECHNETIUM COMPOUNDS; PROSTATIC NEOPLASMS; PROTEIN BINDING; RADIOPHARMACEUTICALS; RECEPTORS, BOMBESIN; TECHNETIUM; TISSUE DISTRIBUTION;

EID: 65749092289     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2009.04.018     Document Type: Article

References (40)

1. + moiety. Nucl. Med. Biol. 33 (2006) 625-634
2. Baidoo K.E., Lin K.S., Zhan Y., Finley P., Scheffel U., and Wagner H.N. Design, synthesis, and initial evaluation of high-affinity technetium bombesin analogues. Bioconjugate Chem. 9 (1998) 218-225
3. Bandoli G., Dolmella A., Porchia M., Refosco F., and Tisato F. Structural overview of technetium compounds (1993-1999). Coord. Chem. Rev. 214 (2001) 43-90
4. 90Y-DOTATOC in association with amino acid infusion: a phase 1 study. Eur. J. Nucl. Med. 30 (2003) 207-216
5. Bogdanov A., Tung C.-H., Bredow S., and Weissleder R. DNA binding chelates for nonviral gene delivery imaging. Gene Ther. 8 (2001) 515-522
6. 2) technetium-99m complexes: synthesis and biological evaluation as potential renal radiopharmaceuticals. J. Med. Chem. 36 (1993) 1032-1040
7. Chen L., and Harrison S.D. Cell-penetrating peptides in drug development: enabling intracellular targets. Biochem. Soc. Trans. 35 (2007) 821-825
8. 111In]-labeled HIV-1 tat peptide radioimmunoconjugates in tumor-bearing mice following intravenous or intratumoral injection. Nucl. Med. Biol. 35 (2008) 101-110
9. Costantini D.L., Hu M., and Reilly R. Peptide motifs for insertion of radiolabeled biomolecules into cells and routing to the nucleus for cancer imaging or radiotherapeutic applications. Cancer Biother. Radiopharm. 23 (2008) 3-23
10. 111In-octreotide. J. Nucl. Med. 41 (2000) 1114-1119
11. Deshayes S., Morris M.C., Divita G., and Heitz F. Interactions of primary amphipathic cell penetrating peptides with model membranes: consequences on the mechanisms of intracellular delivery of therapeutics. Curr. Pharm. Des. 11 (2005) 3629-3638
12. de Visser M., Verwijnen S.M., and de Jong M. Improvement strategies for peptide receptor scintigraphy and radionuclide therapy. Cancer Biother. Radiopharm. 23 (2008) 137-157
13. Dietz G.P., and Bähr M. Delivery of bioactive molecules into the cell: the Trojan horse approach. Mol. Cell. Neurosci. 27 (2004) 85-131
14. Drin G., Cottin S., Blanc E., Rees A., and Temsamani J. Studies on the internalization mechanism of cationic cell penetrating peptides. J. Biol. Chem. 278 (2003) 31192-31201
15. 2: radiochemical evaluation with coligands EDDA (EDDA = ethylenediamine-N,N′-diacetic acid), tricine and nicotinic acid. Synth. React. Inorg. Met.-Org. Nano-Met. Chem. 16 (2005) 438-442
16. 99mTc-UBI 29-41 based on experimental and semiempirical results. Appl. Radiat. Isot. 61 (2004) 1261-1268
17. Ferro-Flores G., Arteaga de Murphy C., and Melendez-Alafort L. Third generation radiopharmaceuticals for imaging and targeted therapy. Curr. Pharm. Anal. 2 (2006) 339-352
18. 3]-bombesin for imaging of GRP receptor-positive tumours. Nucl. Med. Commun. 27 (2006) 371-376
19. 99TcO] apcitide: a technetium labeled peptide. Inorg. Chem. 43 (2004) 2867-2875
20. 3 bombesin analogues. Nucl. Med. Biol. 34 (2007) 17-28
21. Halmos G., Wittliff J.L., and Schally A.V. Characterization of bombesin/gastrin releasing peptide receptors in human breast cancer and their relationship to steroid receptor expression. Cancer Res. 55 (1995) 280-287
22. 123I-labeled HIV-1 tat peptide radioimmuno conjugates are imported into the nucleus of human breast cancer cells and functionally interact in vitro and in vivo with the cyclin-dependent kinase inhibitor, p21(WAF-1/Cip-1). Eur. J. Nucl. Med. Mol. Imaging 34 (2007) 368-377
23. Jain M., Venkatraman G., and Batra S.K. Cell-penetrating peptides and antibodies: a new direction for optimizing radioimmunotherapy. Eur. J. Nucl. Med. Mol. Imaging 34 (2007) 973-977
24. Koch A.M., Reynolds F., Kircher M.F., Merkle H.P., Weissleder R., and Josephson L. Uptake and metabolism of a dual fluorochrome Tat-nanoparticle in HeLa cells. Bioconjugate Chem. 14 (2003) 115-1121
25. Kunstler J.U., Veerendra B., Figueroa S.D., Sieckman G.L., Rold T.L., Hoffman T.J., Smith C.J., and Pietzsch H.J. Organometallic (99m)Tc(III) '4 + 1' Bombesin(7-14) conjugates: synthesis, radiolabeling, and in vitro/in vivo studies. Bioconjugate Chem. 18 (2007) 1651-1716
26. 99mTc(1)-labeled bombesin analogue for imaging of gastrin releasing peptide receptor-positive tumors. Nucl. Med. Biol. 29 (2002) 553-560
27. Lin K.S., Liu A., Baidoo K.E., Hashemzadeh-Gargari H., Chen M.K., Brenneman K., Pili R., Pomper M., Carducci M.A., and Wagner H.N. A new high affinity technetium-99m-bombesin analogue with low abdominal accumulation. Bioconjugate Chem. 16 (2005) 43-50
28. 99mTc-labelled small peptides as diagnostic radiopharmaceuticals. Chem. Rev. 99 (1999) 2235-2251
29. Lui V.W., Thomas S.M., Zhang Q., Wentzel A.L., Siegfried J.M., Li J.Y., and Grandis J.R. Mitogenic effects of gastrin-releasing peptide in head and neck squamous cancer cells are mediated by activation of the epidermal growth factor receptor. Oncogene 22 (2003) 6183-6193
30. Melendez-Alafort L., Ramirez F., de M., Ferro-Flores G., Arteaga de Murphy C., Pedraza-Lopez M., and Hnatowich D.J. Lys and Arg in UBI: a specific site for a stable Tc-99m complex?. Nucl. Med. Biol. 30 (2003) 605-615
31. 99mTc: a preclinical study. J. Med. Chem. 48 (2005) 100-110
32. Reubi J.C. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocrine Rev. 24 (2003) 389-427
33. 3]-bombesin: biokinetics and dosimetry in women. Nucl. Med. Commun. 29 (2008) 741-747
34. Shriver S.P., Bourdeau H.A., Gubish C.T., Tirpak D.L., Davis A.L., Luketich J.D., and Siegfried J.M. Sex-specific expression of gastrin-releasing peptide receptor: relationship to smoking history and risk of lung cancer. J. Natl. Cancer Inst. 92 (2000) 24-33
35. 2]: synthesis, radiolabeling and in vitro/in vivo GRP receptor targeting studies. Anticancer Res. 23 (2003) 63-70
36. Thakur M., and Lentle B.C. Report of a summit on molecular imaging. Radiology 236 (2005) 753-755
37. 99mTc-labeled bombesin-like peptide. Cancer Biother. Radiopharm. 17 (2002) 317-326
38. Youngblood D.S., Hatlevig S.A., Hassinger J.N., Iversen P.L., and Moulton H.M. Stability of cell-penetrating peptide-morpholino oligomer conjugates in human serum and in cells. Bioconjugate Chem. 18 (2007) 50-60
39. 18F-labeled bombesin analogs for targeting GRP receptor-expressing prostate cancer. J. Nucl. Med. 47 (2006) 492-501
40. Zhang Y.-M., Tung C.H., He J., Liu N., Yanachkov I., Liu G., Rusckowski M., and Vanderheyden J.L. Construction of a novel chimera consisting of a chelator-containing Tat peptide conjugated to a morpholino antisense oligomer for technetium-99m labeling and accelerating cellular kinetics. Nucl. Med. Biol. 33 (2006) 263-269